Table 2 Post PCI characteristics at 30, 180, and 360 days from index PCI
30 days after PCI | No psoriasis | Mild psoriasis | Severe psoriasis | p–value |
|---|---|---|---|---|
| Â | n= 49,696 | n=1027 | n=309 | Â |
Male (%) | 35,632 (72.7) | 737 (72.8) | 192 (62.1) | 0.007 |
Female (%) | 14,064 (28.3) | 290 (28.2) | 117 (37.9) | Â |
Primary PCI (%) | 14,451 (29.1) | 268 (26.1) | 90 (29.1) | 0.17 |
Treatment (%) | Â | Â | Â | Â |
  Beta-blocker | 38,916 (78.3) | 772 (75.2) | 230 (74.4) | 0.005 |
  ACE inhibitor/ARB | 25,032 (50.4) | 509 (49.6) | 167 (54.1) | 0.54 |
  Statin | 42,844 (86.2) | 896 (86.3) | 245 (79.3) | 0.049 |
  Platelet inhibitor | 47,949 (96.5) | 991 (96.5) | 285 (92.2) | 0.003 |
  Dual anti-platelet inhibition | 45,901 (92.4) | 946 (92.1) | 273 (88.4) | 0.029 |
  Loop diuretic | 9812 (19.7) | 201 (19.6) | 71 (23.0) | 0.34 |
  Spironolactone | 2852 (5.7) | 53 (5.2) | 23 (7.4) | 0.67 |
  Vitamin K antagonist | 2904 (5.8) | 58 (5.7) | 18 (5.8) | 0.85 |
  Glucose-lowering medication | 5586 (11.2) | 112 (10.9) | 52 (16.8) | 0.039 |
  NSAID | 1349 (2.7) | 40 (3.9) | 34 (11.0) | 0.002 |
180 days after PCI | No psoriasis | Mild psoriasis | Severe psoriasis | p–value |
| Â | n= 46,126 | n=955 | n=279 | Â |
  Beta-blocker | 36,431 (78.9) | 727 (76.1) | 212 (76.0) | 0.05 |
  ACE inhibitor/ARB | 23,324 (50.6) | 484 (50.7) | 153 (54.8) | 0.36 |
  Statin | 40,140 (87.0) | 842 (88.2) | 226 (81.0) | 0.007 |
  Platelet inhibitor | 44,696 (96.9) | 927 (97.1) | 260 (93.2) | 0.002 |
  Dual anti-platelet inhibition | 42,822 (92.8) | 889 (93.1) | 249 (89.3) | 0.07 |
  Loop diuretic | 8968 (19.4) | 188 (19.7) | 62 (22.2) | 0.50 |
360 days after PCI | No psoriasis | Mild psoriasis | Severe psoriasis | p–value |
| Â | n= 42,188 | n=860 | n=257 | Â |
  Beta-blocker | 33,507 (79.4) | 665 (77.3) | 195 (75.9) | 0.124 |
  ACE inhibitor/ARB | 21,389 (50.7) | 430 (50.0) | 140 (54.5) | 0.44 |
  Statin | 36,918 (87.5) | 769 (89.4) | 210 (81.7) | 0.005 |
  Platelet inhibitor | 40,985 (97.2) | 840 (97.7) | 239 (93.0) | <0.001 |
  Dual anti-platelet inhibition | 39,318 (93.2) | 811 (94.3) | 228 (88.7) | 228 (88.7) |
  Loop diuretic | 8055 (19.1) | 161 (18.7) | 52 (20.3) | 0.86 |